AstraZeneca has indicated potential job cuts in the UK if the government enforces profit-sharing regulations on drugs developed from genetic codes, as the pharmaceutical industry resists such measures.
The company's stated concerns arose from discussions at a key government meeting, where proposals for a global levy targeting profits from biodiversity were raised, amid pushback from the industry.
With biodiversity increasingly used in drug development, nations rich in biodiversity feel their genetic resources are being exploited for profit without compensation, labelling it as biopiracy.
At the ongoing biodiversity conference in Cali, Colombia, global leaders are negotiating ways to ensure fair sharing of profits from goods derived from nature's genetic information.
Collection
[
|
...
]